1080685

510(k) Summary

AUG 1 5 2008

Preparation Date:

June 17, 2008

Applicant/Sponsor:

Biomet Trauma (aka EBI; names may be used interchangeably)

100 Interpace Parkway Parsippany, NJ 07054

Contact Person:

Becky Earl/Debra L. Bing

Proprietary Name:

HipLOC™ Compression Hip Screw

Common Name:

Internal fracture fixation device

Classification Name:

Device, Fixation, Proximal Femoral, Implant JDO (CFR 888.3030)

Legally Marketed Devices To Which Substantial Equivalence Is Claimed: Biomet[®] Compression Hip Screw System, K781389; DHS[®] System, Synthes, K981757.

Device Description:

The HipLOC™ Compression Hip Screw is designed as an internal fixation device to provide alignment and strong stabilization for fractures of the proximal femur.

Intended Use:

Indications for the HipLOC™ Compression Hip Screw include open reduction and internal fixation of a wide variety of fractures of the proximal femur: intracapsular fractures, intertrochanteric fractures and subtrochanteric fractures.

Summary of Technologies:

The technological characteristics (materials, sizes, design) are similar or identical to the predicate devices.

Non-Clinical Testing: Non-clinical laboratory testing was performed to determine substantial equivalence. The results indicated that the device was functional within its intended use.

Clinical Testing: None provided as a basis for substantial equivalence.

All trademarks are property of Biomet, Inc., except for the DHS® System which belongs to Synthes.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Biomet Manufacturing Corporation % Ms. Becky Earl Regulatory Specialist P.O. Box 587 Warsaw, Indiana 46581-0587

AUG 1 5 2008

Re: K080685

Trade/Device Name: HipLOC[™] Compression Hip Screw

Regulation Number: 21 CFR 888.3030

Regulation Name: Single/multiple component metallic bone fixation appliances and

accessories

Regulatory Class: II Product Code: JDO, KTT Dated: July 10, 2008 Received: July 14, 2008

Dear Ms. Earl:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Ms. Becky Earl

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Mark of Milkers

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use

Indications for OSC	
510(k) Number (if known):	
Device Name: HipLOC™ Compression Hip Screen	w
Indications for Use:	
Indications for the HipLOC [™] Compression Hip S fixation of a wide variety of fractures of the pro intertrochanteric fractures and subtrochanteric f	ximal femur: intracapsular fractures,
Prescription Use YES AND/OR (Part 21 CFR 801 Subpart D)	Over-The-Counter Use <u>NO</u> (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE	-CONTINUE ON ANOTHER PAGÈ IF NEEDED)
Concurrence of CDRH, Offic	e of Device Evaluation (ODE) Page 1 of 1
and the same of th	Adda for My (Division Sign-Off) Division of General, Restorative, and Neurological Devices
	510(k) Number_ K080685